A5090864408- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Ocular Diseases and Behçet’s Syndrome
- Glaucoma and retinal disorders
- Retinal and Macular Surgery
- Retinal Development and Disorders
- Intraocular Surgery and Lenses
- Systemic Lupus Erythematosus Research
- Vascular Malformations Diagnosis and Treatment
- Ocular Infections and Treatments
- Cytomegalovirus and herpesvirus research
- Optical Coherence Tomography Applications
- Ophthalmology and Visual Impairment Studies
- Vasculitis and related conditions
- Cerebral Venous Sinus Thrombosis
- Ocular Oncology and Treatments
- Drug-Induced Ocular Toxicity
- Syphilis Diagnosis and Treatment
- Sarcoidosis and Beryllium Toxicity Research
- Cerebrovascular and Carotid Artery Diseases
- Complement system in diseases
- RNA Interference and Gene Delivery
- Viral Infectious Diseases and Gene Expression in Insects
- Retinopathy of Prematurity Studies
Duke University
2016-2025
Duke Medical Center
2014-2023
Wills Eye Hospital
2012-2023
Thomas Jefferson University
2023
Duke University Hospital
1997-2022
Vision Eye Institute
2022
Atrium Health Wake Forest Baptist
2022
Ophthalmology Associates (United States)
2021
Retina Associates
2020
Doheny Eye Institute
2016
Clinical trials have established the efficacy of ranibizumab for treatment neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite absence similar supporting data.In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with AMD receive intravitreal injections or on either monthly schedule as needed evaluation. The primary outcome was mean change in visual acuity at 1 year, limit 5 letters eye...
<h3>Purpose</h3> Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD). <h3>Design</h3> Double-masked, multicenter, active-controlled, randomized trials. <h3>Participants</h3> Patients (N = 1817) untreated, active choroidal neovascularization due in the study eye. <h3>Intervention</h3> were intravitreal...
To establish a process to evaluate and standardize state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data.
Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well the adverse effects glucocorticoid therapy. We conducted a trial to assess efficacy and safety adalimumab glucocorticoid-sparing agent treatment uveitis.This multinational phase 3 involved adults who had active intermediate uveitis, posterior or panuveitis despite having received prednisone 2 more weeks. Investigators patients were unaware study-group assignments. randomly...
<h3>Purpose</h3> The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). safety and efficacy avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), C5 inhibitor, were assessed participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study). <h3>Design</h3> International, prospective, randomized, double-masked, sham-controlled, pivotal phase 2/3 clinical trial. <h3>Participants</h3> A total 286 GA AMD. <h3>Main Outcome...
PurposeTo report the 96-week outcomes from HAWK and HARRIER.DesignPhase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy safety of brolucizumab 3 mg (HAWK only) 6 with aflibercept 2 in eyes neovascular age-related macular degeneration (nAMD).ParticipantsTreatment-naïve nAMD were randomized 1:1:1 to (n = 358), 360), 360; HAWK) or 1:1 370), 369; HARRIER).MethodsAfter monthly loading doses, patients received every (q)-12-week (w) dosing, possibly adjusting q8w...
An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK HARRIER trials brolucizumab versus aflibercept neovascular age-related macular degeneration (nAMD).A post hoc analysis a subset data from two 2-year, double-masked, multicenter, active-controlled randomized (NCT02307682, NCT02434328).Patients (N = 1817) with untreated, active...
There is no treatment available for vision loss associated with advanced dry age-related macular degeneration (AMD) or geographic atrophy (GA). In a pilot, proof of concept phase 2 study, we evaluated ciliary neurotrophic factor (CNTF) delivered via an intraocular encapsulated cell technology implant the GA. We designed multicenter, 1-y, double-masked, sham-controlled dose-ranging study. Patients GA were randomly assigned to receive high-or low-dose sham surgery. The primary endpoint was...